AstraZeneca

AstraZeneca's experimental drug disappoints in breast cancer survival trial

The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance compared with chemotherapy, AstraZeneca said.

23 September 2024, 08:36 IST

AstraZeneca's experimental drug disappoints in breast cancer survival trial

23 September 2024, 08:36 IST

AstraZeneca warns of moving UK vaccine production to US: Report

British finance minister Rachel Reeves wants to reduce state provisions to the vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds to 40 million pounds, the report said, citing sources.

23 August 2024, 03:09 IST

AstraZeneca warns of moving UK vaccine production to US: Report

23 August 2024, 03:09 IST

Drugmaker AstraZeneca’s market value soars past $257 billion

AstraZeneca is the UK’s most valuable listed company, having kept a lead over Shell Plc since April, and is ranked seventh in Europe by market value in dollar terms.

14 August 2024, 10:27 IST

Drugmaker AstraZeneca’s market value soars past $257 billion

14 August 2024, 10:27 IST

AstraZeneca's Covid prevention drug application gets EU fast-track assessment

'The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use (CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation,' the Anglo-Swedish drugmaker said.

01 July 2024, 07:57 IST

AstraZeneca's Covid prevention drug application gets EU fast-track assessment

01 July 2024, 07:57 IST

AstraZeneca's Imfinzi fails in late-stage trial to treat certain type of lung cancer

The latest results were a contrast to the ones published in April, when the Anglo-Swedish drugmaker said Imfinzi, in a separate trial, helped improve survival in patients in the early stages of small-cell, or aggressive type, of lung cancer, meeting two key trial goals.

25 June 2024, 07:31 IST

AstraZeneca's Imfinzi fails in late-stage trial to treat certain type of lung cancer

25 June 2024, 07:31 IST

AstraZeneca's Enhertu breast cancer trial shows 'unprecedented' results, slows progression of disease

The findings, presented in Chicago at the annual meeting of the American Society of Clinical Oncology, significantly broaden the range of breast cancer patients that could benefit from Enhertu, an antibody-drug conjugate designed to deliver toxic chemotherapy directly to tumors.

03 June 2024, 01:18 IST

AstraZeneca's Enhertu breast cancer trial shows 'unprecedented' results, slows progression of disease

03 June 2024, 01:18 IST

DCGI orders withdrawal of AstraZeneca's cancer drug Olaparib for certain treatments

In a communication sent to the regulators on May 16, the DCGI stated that the firm AstraZeneca Pharma India Limited has submitted an application to them for the withdrawal of indications for Olaparib Tablets 100mg and 150mg in the treatment of patient with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

23 May 2024, 03:23 IST

DCGI orders withdrawal of AstraZeneca's cancer drug Olaparib for certain treatments

23 May 2024, 03:23 IST

AstraZeneca to build $1.5-billion cancer drug plant in Singapore

It plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), which will be the drugmaker's first end-to-end ADC production site.

20 May 2024, 10:02 IST

AstraZeneca to build $1.5-billion cancer drug plant in Singapore

20 May 2024, 10:02 IST

AstraZeneca's Covid prevention drug meets primary goals in late-stage study

The investigational long-acting antibody therapy called sipavibart showed a 'statistically significant reduction' in symptomatic Covid-19 cases in an immunocompromised patient population, the company said.

16 May 2024, 06:47 IST

AstraZeneca's Covid prevention drug meets primary goals in late-stage study

16 May 2024, 06:47 IST

Woman 'permanently disabled' after AstraZeneca Covid vaccine trial, lawsuit in US claims: Report

42-year-old Brianne Dressen has claimed that she developed a neurological condition after partaking in the vaccine trial in 2020. In the UK, over 50 people have filed lawsuits against the company.

15 May 2024, 07:34 IST

Woman 'permanently disabled' after AstraZeneca Covid vaccine trial, first lawsuit in US filed against company: Report

Woman 'permanently disabled' after AstraZeneca Covid vaccine trial, lawsuit in US claims: Report

15 May 2024, 07:34 IST